Franklin多部门收入主动型ETF MULT 深 沪
已收盘 07-02 16:00:00 美东时间
25.10
+0.040
+0.16%
华盛通- 最 高25.10
- 今 开25.06
- 成交量 8股
- 最 低 25.10
- 昨 收 25.06
- 总市值 1506.00万
- 52周最高 25.112
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 24.1074
- 委 比 -66.67%
- 总股本 60.00万
- 历史最高 25.10
- 量 比 0
- 振 幅 0.00%
- 历史最低 24.1074
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Nvidia Partners With AI Clouds For Revenue-Sharing & Credit-Support Model
BRIEF-Nvidia Partners With AI Clouds For Revenue-Sharing & Credit-Support Model July 1 (Reuters) - NVIDIA Corp NVDA.O : NVIDIA: PARTNERING WITH AI CLOUDS TO DEPLOY LARGE‑SCALE, MULTI‑TENANT AI FACTORIES, THROUGH A REVENUE-SHARING AND CREDIT-SUPPORT MODEL Source text: https://tinyurl.com/4zxuankt Fur
07-02 11:41
BRIEF-Tekna Gets $8.1 Mln Multi Plasma System Order
BRIEF-Tekna Gets $8.1 Mln Multi Plasma System Order June 30 (Reuters) - Tekna Holding ASA TEKNA.OL : SECURES USD 8.1 MILLION MULTI PLASMA SYSTEM ORDER FROM NEW US CRITICAL MINERALS CUSTOMER Source text: ID:nObiC4tJHa Further company coverage: TEKNA.OL (Gdansk Newsroom) (( gdansk.newsroom@thomsonreut
06-30 15:16
BRIEF-Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly
BRIEF-Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly June 24 (Reuters) - Abbisko Cayman Ltd 2256.HK : THERAPEUTICS ENTERS STRATEGIC RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH ELI LILLY ABBISKO THERAPEUTICS AND LILLY TO COLLABORATE ON MULTIPLE
06-24 08:10
BRIEF-Arcelormittal Partners With AWS On Industrial Automation
BRIEF-Arcelormittal Partners With AWS On Industrial Automation June 22 (Reuters) - ArcelorMittal SA MT.LU : ARCELORMITTAL ANNOUNCES STRATEGIC COLLABORATION WITH AWS TO DRIVE INDUSTRIAL AUTOMATION AND LOWER-CARBON CONSTRUCTION GLOBALLY AWS TO DELIVER EDUCATION PROGRAMME FOR ARCELORMITTAL GLOBAL WORKF
06-22 14:03
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma June 19 (Reuters) - Sanofi SA SASY.PA : PRESS RELEASE: SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION APPROVED IN JAPAN FOR PATIENTS WITH MULTIPLE MYELOMA APPROVAL BASED ON IRAKLIA PHASE 3 STUDY SHOWING
06-19 18:33
BRIEF-Parsons Awarded $22M Contract For Los Angeles’ I-605 Multimodal Corridor Improvements
BRIEF-Parsons Awarded $22M Contract For Los Angeles’ I-605 Multimodal Corridor Improvements June 11 (Reuters) - Parsons Corp PSN.N : PARSONS AWARDED $22M CONTRACT FOR LOS ANGELES’ I-605 MULTIMODAL CORRIDOR IMPROVEMENTS Source text: ID:nGNX64NyGt Further company coverage: PSN.N (( Reuters.Briefs@thom
06-11 18:32
GRAPHIC-SpaceX by the numbers: Six charts mapping businesses driving its IPO ambitions
GRAPHIC-SpaceX by the numbers: Six charts mapping businesses driving its IPO ambitions By Anhata Rooprai and Jaspreet Singh June 11 (Reuters) - SpaceX's market debut on Friday is expected to be the largest-ever IPO , capping the meteoric rise of a company that has reshaped the space business with re
06-11 18:03
FACTBOX-Air India's long history as it continues to face fallout from deadly crash
FACTBOX-Air India's long history as it continues to face fallout from deadly crash Recasts with latest on investigation, updates details on Air India throughout June 11 (Reuters) - Indian investigators are expected to delay issuing a final report into a deadly Air India Boeing BA.N 787 crash by the
06-11 12:50
BRIEF-GSK CEO Says Don't Need Nuvalent Deal To Achieve £40 Bln Sales Target
BRIEF-GSK CEO Says Don't Need Nuvalent Deal To Achieve £40 Bln Sales Target June 9 (Reuters) - GSK plc GSK.L : GSK CEO LUKE MIELS SAYS NUVALENT DEAL SIZE IS LARGER THAN USUAL BRACKET BECAUSE IT WAS "UNUSUAL" TO GET MULTIPLE PRODUCTS IN ONE DEAL GSK CEO: WORKING TO OFFSET COST OF SERVICING THE DEBT F
06-09 15:19
UPDATE 4-GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover
UPDATE 4-GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover Deal values cancer drug developer Nuvalent at $124 per share That is a 40% premium to the US-listed firm's close on Monday GSK CEO Miels says deals expands lung cancer treatments Deal size a departure from smaller bolt-on deal
06-09 14:06
